Search

Search Constraints

You searched for: Author/Creator Grzasko, Norbert

Search Results

1. A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk. Issue 2 (1st October 2022)

2. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients. Issue 1 (6th June 2012)

3. All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. (January 2019)

4. Central nervous system involvement by multiple myeloma: A multi‐institutional retrospective study of 172 patients in daily clinical practice. Issue 6 (24th April 2016)

5. Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group. Issue 9 (2nd September 2017)

6. Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients. Issue 2 (30th March 2021)

7. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. Issue 22 (1st August 2021)

8. Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies. (8th May 2019)

9. Phase 2 study of all‐oral ixazomib, cyclophosphamide and low‐dose dexamethasone for relapsed/refractory multiple myeloma. (20th November 2018)

10. The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real‐world" study: Polish Myeloma Group experience. (12th July 2018)